Breo Coverage Gaining Ground, GSK’s Witty Assures Investors
This article was originally published in The Pink Sheet Daily
GlaxoSmithKline’s COPD drug Breo Ellipta is facing reimbursement challenges, particularly in terms of Medicare Part D coverage. But CEO Andrew Witty told investors during a year-end sales and earnings call Feb. 5 that coverage is increasing and will continue to grow through 2014.
You may also be interested in...
The EMA has recommended for authorization drugs from GSK, Novartis and Teva, setting the scene for a show-down in the increasingly competitive European COPD respiratory market.
Germany’s IQWiG has cleared Boehringer’s Giotrif for lung cancer and Novartis’ Ultibro Breezhaler for COPD, raising questions as to what HTA submission strategy drugs firms should adopt.
FDA approved GSK’s Anoro Ellipta as the first LABA/LAMA combination product in the U.S. for the maintenance treatment of COPD Dec. 18, positioning GSK to launch a second respiratory product months after launching Breo Ellipta.